11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Tamoxifen Mylan

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Tamoxifen

Tamoxifen

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Neyman A, Eugster EA. Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017. Pediatr Endocrinol Rev. 2017;15(2):136-141.

  2. Zehetner A. Tamoxifen to treat male pubertal gynaecomastia. Int J Pediatr Adolesc Med. 2015;2(3):152-156.

  3. Tamoxifen Sandoz (tamoxifen). Summary of Prodruct Characteristics. Swedish Medical Products Agency [updated 2018-06-13, cited 2019-10-03].

  4. Fentiman IS. Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol. 2016;101(1):119-24.

  5. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V et al. 13th st Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). Breast Care (Basel). 2013;8(3):221-9.

  6. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-41.

  7. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA17. Ann Oncol. 2008;19(5):877-82.

  8. Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(9):1211-1220.

  9. Cantwell BM, Tong D, Minton M, Rubens RD, Hayward JL. Tamoxifen and male breast cancer. Lancet. 1978;2(8089):582-3.

  10. Patterson JS, Battersby LA, Bach BK. Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep. 1980;64(6):801-4.

  11. Ribeiro GG. The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer. 1976;33(4):465-7.

  12. Bezwoda WR, Hesdorffer C, Dansey R, de Moor N, Derman DP, Browde S et al. Breast cancer in men Clinical features, hormone receptor status, and response to therapy. Cancer. 1987;60(6):1337-40.

  13. Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT et al. [Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne. 2004;25(4):323-4.

  14. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol. 2007;9(3):192-4.

  15. Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat. 2013;141(1):119-23.

  16. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013;108(11):2259-63.

  17. Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21(6):1243-5.

  18. Eggemann H, Altmann U, Costa SD, Ignatov A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J Cancer Res Clin Oncol. 2018;144(2):337-341.

  19. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int. 2007;1(2):287-94.

  20. Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003;180(1):129-34.

  21. Ma J, Malladi S, Beck AH. Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer. Sci Rep. 2016;6(1):19119.

  22. Ivanova MM, Mazhawidza W, Dougherty SM, Klinge CM. Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. Am J Respir Cell Mol Biol. 2010;42(3):320-30.

  23. Mitkov M, Joseph R, Copland J. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol. 2015;417(1):94-102.

  24. Beguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs non-tamoxifen treatment for advanced melanoma: a meta-analysis. Int J Dermatol. 2010;49(10):1194-202.

  25. Nowak AK, Stockler MR, Chow PK, Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma A systematic review. Cancer. 2005;103(7):1408-14.

  26. Castells A, Bruix J, Brú C, Ayuso C, Roca M, Boix L et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995;109(3):917-22.

  27. Barbare J‐C, Milan C, Bouché O, et al. Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen: a phase III trial in 420 patients [abstract 551]. Proc Am Soc Clin Oncol. 2002;21(1):138A.

  28. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459-78.

  29. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-6.

  30. Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74(1):74-7.

  31. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17(5):17-21.

  32. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012;23(6):1471-4.

  33. Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J Clin Endocrinol Metab. 2012;97(4):E521-7.

  34. Birzniece V, Ho KK. Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. Eur J Endocrinol. 2015;173(4):479-87.

  35. Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007;132(3):938-43.

  36. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-10-29.]

  1. Neyman A, Eugster EA. Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017. Pediatr Endocrinol Rev. 2017;15(2):136-141.
  2. Zehetner A. Tamoxifen to treat male pubertal gynaecomastia. Int J Pediatr Adolesc Med. 2015;2(3):152-156.
  3. Tamoxifen Sandoz (tamoxifen). Summary of Prodruct Characteristics. Swedish Medical Products Agency [updated 2018-06-13, cited 2019-10-03].
  4. Fentiman IS. Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol. 2016;101(1):119-24.
  5. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V et al. 13th st Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). Breast Care (Basel). 2013;8(3):221-9.
  6. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-41.
  7. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA17. Ann Oncol. 2008;19(5):877-82.
  8. Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(9):1211-1220.
  9. Cantwell BM, Tong D, Minton M, Rubens RD, Hayward JL. Tamoxifen and male breast cancer. Lancet. 1978;2(8089):582-3.
  10. Patterson JS, Battersby LA, Bach BK. Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep. 1980;64(6):801-4.
  11. Ribeiro GG. The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer. 1976;33(4):465-7.
  12. Bezwoda WR, Hesdorffer C, Dansey R, de Moor N, Derman DP, Browde S et al. Breast cancer in men Clinical features, hormone receptor status, and response to therapy. Cancer. 1987;60(6):1337-40.
  13. Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT et al. [Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne. 2004;25(4):323-4.
  14. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol. 2007;9(3):192-4.
  15. Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat. 2013;141(1):119-23.
  16. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013;108(11):2259-63.
  17. Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21(6):1243-5.
  18. Eggemann H, Altmann U, Costa SD, Ignatov A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J Cancer Res Clin Oncol. 2018;144(2):337-341.
  19. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int. 2007;1(2):287-94.
  20. Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003;180(1):129-34.
  21. Ma J, Malladi S, Beck AH. Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer. Sci Rep. 2016;6(1):19119.
  22. Ivanova MM, Mazhawidza W, Dougherty SM, Klinge CM. Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. Am J Respir Cell Mol Biol. 2010;42(3):320-30.
  23. Mitkov M, Joseph R, Copland J. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol. 2015;417(1):94-102.
  24. Beguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs non-tamoxifen treatment for advanced melanoma: a meta-analysis. Int J Dermatol. 2010;49(10):1194-202.
  25. Nowak AK, Stockler MR, Chow PK, Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma A systematic review. Cancer. 2005;103(7):1408-14.
  26. Castells A, Bruix J, Brú C, Ayuso C, Roca M, Boix L et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995;109(3):917-22.
  27. Barbare J‐C, Milan C, Bouché O, et al. Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen: a phase III trial in 420 patients [abstract 551]. Proc Am Soc Clin Oncol. 2002;21(1):138A.
  28. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459-78.
  29. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4):602-6.
  30. Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74(1):74-7.
  31. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17(5):17-21.
  32. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012;23(6):1471-4.
  33. Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J Clin Endocrinol Metab. 2012;97(4):E521-7.
  34. Birzniece V, Ho KK. Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. Eur J Endocrinol. 2015;173(4):479-87.
  35. Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007;132(3):938-43.
  36. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-10-29.]